President Donald Trump's administration has decided not to cover expensive, high-demand obesity treatments under the ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

It seems like everyone and their sister is taking a GLP-1 (“glucagon-like peptide-1 receptor agonists,” if you’re feeling nasty), or is at least thinking about it. These meds—which include Ozempic, ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 among U.S. adults without diabetes. The research, published April 1 in the ...

As semaglutide-based weight loss treatments such as Ozempic and Wegovy become more popular, new side effects are emerging – ...

The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...

Affordable and alternative versions of popular weight loss drugs like Ozempic and Wegovy may no longer be available. The FDA ...

Ozempic and other semaglutide medications (including Wegovy and Rybelsus) have changed the lives of millions of Americans ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...